Efficacy of hydrocortisone acetate/hyaluronidase vs triamcinolone acetonide/hyaluronidase in the treatment of oral submucous fibrosis.
OBJECTIVE
Oral submucous fibrosis is a common premalignant condition caused by chewing arecanut and other irritants in various forms. Its medical treatment is not yet fully standardized, although the optimal doses of its medical treatment is in the form of hydrocortisone acetate combined with hyaluronidase. The problem with the prevailing treatment was injections at weekly interval. In this study we compared the efficacy of hydrocortisone acetate and hyaluronidase at weekly interval versus triamcinolone acetonide and hyaluronidase at 15 days interval.


METHODS
Patients of OSMF (100) were randomly divided into two groups A and B. Group A patients received combination of hydrocortisone acetate (1.5 ml)/hyaluronidase (1500 IU) at weekly interval submucosally in pterygomandibular raphe, half dose on each side for 22 wk. Group B patients received combination of triamcinolone acetonide (10 mg/ml)/ hyaluronidase (1500 IU) at 15 days interval for 22 wk. Treatment outcome was evaluated on the basis of improvement in symptom score, sign score and histopathological improvement. Student's 't' test was applied for comparing the results.


RESULTS
No statistically significant difference in symptom score, sign score and histopathological improvement was seen between the two groups.


CONCLUSIONS
Treatment regimen of group B was more convenient to the patients because less number of visits required and cheap. No side effects were seen. A follow up study is required to see long term effects.
Singh
Mangal
M
Department of E.N.T. & Head & Neck Surgery, S.R.N. Hospital, Allahabad, India. drmangalsingh@rediffmail.com
Niranjan
H S
HS
Mehrotra
Ravi
R
Sharma
Devashish
D
Gupta
S C
SC
D000293:Adolescent; D000328:Adult; D000368:Aged; D005260:Female; D005355:Fibrosis / Q000188:drug therapy*; D006801:Humans; D006821:Hyaluronoglucosaminidase / Q000008:administration & dosage / Q000627:therapeutic use*; D006854:Hydrocortisone / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009059:Mouth Diseases / Q000188:drug therapy*; D009092:Mucous Membrane; D011446:Prospective Studies; D016037:Single-Blind Method; D014222:Triamcinolone Acetonide / Q000008:administration & dosage / Q000627:therapeutic use*; D055815:Young Adult
C021650:hydrocortisone acetate; D006821:Hyaluronoglucosaminidase; D014222:Triamcinolone Acetonide; D006854:Hydrocortisone